PET tau imaging in BLSA and GESTALT as an Early Marker of Alzheimer's Disease

2016年，BLSA研究引入了使用Tau放射性配基AV-1451的PET成像。结合PET淀粉样成像和核磁共振测量，这些研究将提供阿尔茨海默病临床前阶段的信息。到目前为止，超过115名BLSA参与者至少进行了一次PET Tau扫描，其中超过一半的人进行了两次或更多扫描。以往的研究表明，较大的内源性tau水平与更剧烈的记忆丧失之间存在关联，同时tau负担与人格特征之间也存在关联。 除了PET生物标记物的研究外，我们还在研究接受PET淀粉样蛋白和tau研究的个体样本中AD病理和神经变性的血浆生物标记物。这些化验已经在我们的合作者，约翰霍普金斯大学的Abhay Moghekar博士，哥德堡大学的Zetterberg，Blennow和Ashton博士的实验室进行过。正在进行的分析正在使用体素分析来检查这些AD生物标记物与PET Tau结合(和PET淀粉样蛋白)的空间分布之间的关系，最近的结果在阿尔茨海默病协会国际会议(Bilel等人，2023年)上公布。

PET imaging with the Tau radioligand AV-1451 was introduced into the BLSA study in 2016. In combination with PET amyloid imaging and MRI measures, these studies will provide information on the preclinical stages of Alzheimer's Disease. To date more than 115 BLSA participants had at least one PET Tau scan, and of these, more than half had 2 or more scans. Past publications have shown associations between greater entorhinal tau levels and steeper memory loss, as well as associations between tau burden and personality characteristics. In addition to the study of PET biomarkers, we are investigating plasma biomarkers of AD pathology and neurodegeneration in the sample of individuals who have undergone PET amyloid and tau studies. These assays have been performed in the laboratories of our collaborators, Dr. Abhay Moghekar at Johns Hopkins, and Drs. Zetterberg, Blennow and Ashton at Gothenburg University. Ongoing analyses are examining the relation between these AD biomarkers and the spatial distribution of PET Tau binding (and PET amyloid) using voxel wise analysis, with recent results presented at the Alzheimer's Association International Conference (Bilgel et al., 2023).